Advertisement
AXON vs SEER
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Seer (SEER) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) commands a market capitalization exceeding $32 billion with year-to-date (YTD) gains of approximately 29%, dwarfing Seer (SEER)'s $114 million market cap and 11% YTD rise.
- AXON benefits from robust demand in public safety technology, including AI-enhanced tools, while SEER faces challenges in proteomics research amid funding uncertainties.
- Recent market activity shows AXON shares pulling back despite strong software revenue growth, contrasting SEER's volatility from a rejected acquisition proposal.
- AXON trades at a trailing price-to-earnings (P/E) ratio of 263, reflecting premium valuation, while SEER lacks profitability with no P/E available.
- Analysts maintain overweight ratings on AXON with targets around $700, signaling upside potential over SEER's equal-weight stance.
Introduction
This comparison examines AXON and SEER, two stocks representing distinct sectors—public safety technology and life sciences proteomics. Traders seeking exposure to innovative tech with recurring revenue streams may eye AXON, while those interested in high-risk biotech plays might consider SEER. Investors analyzing relative performance, momentum shifts, and market positioning in recent weeks will find insights into growth trajectories, valuation contrasts, and sector-specific catalysts. This analysis draws on verifiable data to highlight trade-offs for diversified portfolios or tactical trades.
AXON Overview and Recent Performance
Axon Enterprise (AXON), headquartered in Scottsdale, Arizona, develops public safety solutions including conducted energy devices under the TASER brand, body cameras, and cloud-based software-as-a-service (SaaS) platforms like Axon Evidence for digital evidence management. The company serves first responders globally through hardware sales and recurring software subscriptions. In recent market activity, shares have traded around $402, down significantly from the 52-week high of $886 but above the low of $339, with YTD gains of 29%. Strong quarterly results showed 40% growth in software and services revenue, bolstered by new AI tools addressing data overload in public safety. Sentiment reflects optimism for 27-30% revenue expansion, tempered by recent pullbacks and high valuation concerns ahead of upcoming earnings.
SEER Overview and Recent Performance
Seer (SEER), based in Redwood City, California, provides proteomics tools via its Proteograph suite, featuring engineered nanoparticles, automation, and analytics software for research in academic and biopharma labs. The platform enables deep proteome analysis for non-clinical use. Shares recently closed near $2.03, within a tight 52-week range of $1.65 to $2.41, posting YTD gains of 11%. Recent developments include fiscal year revenue of $16.6 million, up 17% year-over-year but missing expectations due to funding delays, alongside rejection of an unsolicited $2.35 per share acquisition bid from the Radoff-JEC Group. Performance has been volatile, influenced by NIH budget pressures and strategic independence focus.
Trending AI Robots
Tickeron's Trending AI Robots page curates 25 top-performing AI trading bots from hundreds available, each scanning thousands of tickers for optimal trades amid current market conditions. These bots showcase diverse strategies, with annualized returns ranging from 24% to 163%, win rates of 51% to 88%, and profit factors up to 11.7 across short-term (hours) to multi-week holds. Examples include bots with 88% win rates on semiconductor tickers or 126% returns on leveraged ETFs. Traders can explore these for automated pattern recognition in stocks like AXON or SEER, tailoring to risk preferences. Visit Trending AI Robots to evaluate live performance and copy top signals.
Head-to-Head Comparison
AXON and SEER diverge sharply in business models: AXON's hybrid hardware-SaaS generates recurring revenue from public safety contracts, while SEER's research tools rely on lumpy biopharma sales. Growth drivers favor AXON's AI integrations and device demand over SEER's modest proteomics adoption amid funding hurdles. Recent momentum shows AXON resilient YTD despite dips, versus SEER's takeover-driven swings. Risks include AXON's elevated P/E and debt, and SEER's small-cap illiquidity and losses. Sector exposure pits AXON's stable industrials/tech against SEER's volatile biotech. Market sentiment leans positive for AXON via analyst targets, while SEER contends with acquisition uncertainty.
Tickeron AI Verdict
Tickeron's AI models would likely favor AXON in the current environment, given its superior trend consistency, scale advantages, SaaS-driven stability, and catalysts like AI public safety expansions. SEER offers speculative upside from proteomics potential or M&A (mergers and acquisitions), but higher volatility and slower growth reduce probabilistic appeal for trend-following strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Buy and SEER is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileSEER’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- SEER’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while SEER’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 6 bearish.
- SEER’s TA Score: 4 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -9.13% price change this week, while SEER (@Biotechnology) price change was -3.91% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.16%. For the same industry, the average monthly price growth was +2.06%, and the average quarterly price growth was +17.36%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
SEER is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Aerospace & Defense (-1.16% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+0.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | SEER | AXON / SEER | |
| Capitalization | 35.6B | 94.6M | 37,632% |
| EBITDA | 320M | -68.48M | -467% |
| Gain YTD | -22.221 | -6.011 | 370% |
| P/E Ratio | 178.12 | N/A | - |
| Revenue | 2.98B | 14.7M | 20,293% |
| Total Cash | 737M | 167M | 441% |
| Total Debt | 1.83B | 23M | 7,948% |
AXON | ||
|---|---|---|
OUTLOOK RATING 1..100 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 66 | |
SMR RATING 1..100 | 82 | |
PRICE GROWTH RATING 1..100 | 60 | |
P/E GROWTH RATING 1..100 | 58 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AXON | SEER | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 69% | 3 days ago 77% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 81% |
| MACD ODDS (%) | 3 days ago 83% | 3 days ago 84% |
| TrendWeek ODDS (%) | 3 days ago 67% | 3 days ago 84% |
| TrendMonth ODDS (%) | 3 days ago 72% | 3 days ago 83% |
| Advances ODDS (%) | 13 days ago 74% | 3 days ago 75% |
| Declines ODDS (%) | 3 days ago 69% | 10 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 69% | N/A |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 78% |
Advertisement
SEER and
Correlation & Price change
A.I.dvisor indicates that over the last year, SEER has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SEER jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To SEER | 1D Price Change % | ||
|---|---|---|---|---|
| SEER | 100% | +1.18% | ||
| AXON - SEER | 56% Loosely correlated | -1.00% | ||
| ARRY - SEER | 47% Loosely correlated | +4.30% | ||
| RNA - SEER | 40% Loosely correlated | -0.48% | ||
| DNA - SEER | 37% Loosely correlated | -1.38% | ||
| VCYT - SEER | 35% Loosely correlated | -0.19% | ||
More | ||||